These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36612009)

  • 41. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know.
    Downs-Canner S; Weiss A
    Clin Breast Cancer; 2024 Jun; 24(4):328-336. PubMed ID: 38616443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy.
    Patel BK; Hilal T; Covington M; Zhang N; Kosiorek HE; Lobbes M; Northfelt DW; Pockaj BA
    Ann Surg Oncol; 2018 May; 25(5):1350-1356. PubMed ID: 29516362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.
    Virnig BA; Tuttle TM; Shamliyan T; Kane RL
    J Natl Cancer Inst; 2010 Feb; 102(3):170-8. PubMed ID: 20071685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.
    Lee CW; Wu HK; Lai HW; Wu WP; Chen ST; Chen DR; Chen CJ; Kuo SJ
    Eur J Radiol; 2016 Apr; 85(4):780-9. PubMed ID: 26971424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overuse of Axillary Surgery in Patients with Ductal Carcinoma In Situ: Opportunity for De-escalation.
    Piltin MA; Hoskin TL; Day CN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2022 Nov; 29(12):7705-7712. PubMed ID: 35789303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does the volume of ductal carcinoma in situ impact the positive margin rate in patients undergoing breast conservation for invasive breast cancer?
    Martin-Dunlap TM; Cyr AE; Al Mushawah F; Gao F; Margenthaler JA
    J Surg Res; 2013 Sep; 184(1):228-33. PubMed ID: 23688789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study.
    Lopez Gordo S; Blanch Falp J; Lopez-Gordo E; Just Roig E; Encinas Mendez J; Seco Calvo J
    Int J Surg; 2019 Mar; 63():98-106. PubMed ID: 30738200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-operative radiotherapy for ductal carcinoma in situ of the breast.
    Goodwin A; Parker S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2009 Jan; (1):CD000563. PubMed ID: 19160183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy.
    Pendas S; Jakub J; Giuliano R; Gardner M; Swor GB; Reintgen DS
    Cancer Control; 2004; 11(4):231-5. PubMed ID: 15284714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
    Yan Y; Zhang L; Tan L; Ma X; Zhang Y; Shao S; Liu J; Xue C; Li Z; Zhang X; Drokow EK; Shi X; Ren J
    Pathol Oncol Res; 2020 Jan; 26(1):521-531. PubMed ID: 30499075
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
    Scheel JR; Kim E; Partridge SC; Lehman CD; Rosen MA; Bernreuter WK; Pisano ED; Marques HS; Morris EA; Weatherall PT; Polin SM; Newstead GM; Esserman LJ; Schnall MD; Hylton NM;
    AJR Am J Roentgenol; 2018 Jun; 210(6):1376-1385. PubMed ID: 29708782
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current Therapeutic Approaches to DCIS.
    Doke K; Butler S; Mitchell MP
    J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):279-291. PubMed ID: 30267199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
    Thompson BM; Chala LF; Shimizu C; Mano MS; Filassi JR; Geyer FC; Torres US; de Mello GGN; da Costa Leite C
    Eur Radiol; 2022 Mar; 32(3):1663-1675. PubMed ID: 34716780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.
    Tasoulis MK; Lee HB; Yang W; Pope R; Krishnamurthy S; Kim SY; Cho N; Teoh V; Rauch GM; Smith BD; Valero V; Mohammed K; Han W; MacNeill F; Kuerer HM
    JAMA Surg; 2020 Dec; 155(12):e204103. PubMed ID: 33026457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients.
    Koelbel V; Pfob A; Schaefgen B; Sinn P; Feisst M; Golatta M; Gomez C; Stieber A; Bach P; Rauch G; Heil J
    Ann Surg Oncol; 2022 Feb; 29(2):1076-1084. PubMed ID: 34581923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
    LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
    Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of ductal carcinoma in situ with nipple discharge. Intraductal spreading of carcinoma is an unfavorable pathologic factor for breast-conserving surgery.
    Ohuchi N; Furuta A; Mori S
    Cancer; 1994 Aug; 74(4):1294-302. PubMed ID: 8055451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.